Belgium-based cancer therapies developer eTheRNA Immunotherapies has initiated a Phase Ib clinical trial of TriMix-MEL (ECI-006) to treat patients with metastatic melanoma.

TriMix-MEL is an investigational immunotherapy that consists of three protein-encoding mRNAs, as well as mRNAs that encode five melanoma-associated antigens.

The Phase Ib trial will investigate the immunogenicity, safety and tolerability of TriMix-MEL in-vivo over 14 weeks in stage IIc/III/IV melanoma patients who show no evidence disease following surgical tumour removal but are at risk of recurrence.

Five intranodal administrations of the investigational immunotherapy will be evaluated during the trial, which will be carried out in countries including Belgium and Spain.

The preliminary top-line results from the trial are expected to be reported in late 2017.

"We are excited by the potential of our TriMix-based in-vivo immunotherapies to deliver long-lasting clinical remission, alone or in combination therapy, to a broad range of cancer patients."

eTheRNA CEO Dirk Reyn said: “We are looking forward to generating more clinical data to validate the broader use of our TriMix technology platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Based on the data we have generated to date, we are excited by the potential of our TriMix-based in-vivo immunotherapies to deliver long-lasting clinical remission, alone or in combination therapy, to a broad range of cancer patients so they can enjoy more years of good quality life."

In other Phase I/II trials, TriMix ex-vivo immunotherapy is reported to have demonstrated clear signs of clinical anti-tumour activity.

The firm is planning to further validate the ability of TriMix as an immune activator in combination with antigens or as a standalone tumour environment enhancer in various clinical trials, of which certain studies will involve optimal route of administration of in-vivo immunotherapies.


Image: Histopathologic image of melanoma. Photo: courtesy of KGH / Wikipedia.